Enanta Pharmaceuticals share price logo

Enanta Pharmaceuticals

NASDAQ: ENTA

Small Cap

$12.96

+0.12

(+0.93%)

as on

Enanta Pharmaceuticals Stock Performance

as on October 3, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $12.58
    $13.21
    downward going graph

    2.93%

    Downside

    1.93%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $10.12
    $17.15
    downward going graph

    21.88%

    Downside

    32.33%

    Upside

    downward going graph

Enanta Pharmaceuticals share price movements today

Previous Close
$12.84
Open
$12.84
Volume
946.5K
Market Cap
$374.0M
Day's Low - High
$12.58 - $13.21
52 Week Low - High
$10.12 - $17.15

Enanta Pharmaceuticals Historical Returns

1 Month Return
-7.56 %
3 Month Return
-14.23 %
1 Year Return
+ 25.46 %
3 Year Return
+ 20.22 %
5 Year Return
-78.74 %

Enanta Pharmaceuticals Stock Fundamentals & Key Indicators

Check Enanta Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$374.0M

EPS (TTM)

-2.41

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.66%

PE Ratio (TTM)

-5.39

Industry PE ratio

-6.16

PEG Ratio

-0.08

EBITDA

-46.5M

Revenue (TTM)

65.3M

Profit Margin

98.15%

Return On Equity TTM

-61.84%

Enanta Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Enanta Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$374.0M-78.74%-5.3998.15%0.00%
StrongBuy$44.1B609.62%-23.340.00%0.00%
Neutral$75.4B-44.29%-24.08-12.57%0.00%
StrongBuy$132.5B180.98%30.1986.04%0.00%
Buy$78.1B28.80%17.6784.86%0.50%

Stock Returns calculator for Enanta Pharmaceuticals Stock including INR - Dollar returns

The Enanta Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Enanta Pharmaceuticals investment value today

Current value as on today

₹1,36,156

Returns

₹36,156

(+36.16%)

Returns from Enanta Pharmaceuticals Stock

₹25,460 (+25.46%)

Dollar Impact

₹10,696 (+10.7%)

Analyst Recommendation on Enanta Pharmaceuticals Stock

Based on 14 analysts

BUY

64.29%

Buy

28.57%

Hold

7.14%

Sell

Based on 14 analysts, 64.29% of analysts recommend a 'BUY' rating for Enanta Pharmaceuticals. Average target price of $21.83

Enanta Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Enanta Pharmaceuticals.

What analysts predicted

40.63%UPSIDE

Target Price

$21.83

Current Price

$12.96

Analyzed by

14 Analysts

Target

$21.83

Enanta Pharmaceuticals target price $21.83, a slight upside of 40.63% compared to current price of $12.96. According to 14 analysts rating.

Indian Investors' Interest in Enanta Pharmaceuticals Stock

Search interest for Enanta Pharmaceuticals Stock has decreased by -52% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-52% versus previous 30 day period

Enanta Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
17
17
14
16
14
18
15
18
17
14
Gross Profit
17
17
14
16
14
18
15
18
15
14
Operating Income
-32
-24
-29
-23
-24
-18
-18
-11
-11
-17
EBITDA
-28
-20
-26
-19
-21
-15
-14
-7
-8
-15
Interest Expense
2
2
2
1
1
1
2
3
3
4
Depreciation
0
0
0
0
1
1
1
1
1
-
Income Before Tax
-31
-23
-29
-22
-23
-18
-18
-11
-13
-19
Income Tax Expense
0
0
0
0
-1
0
0
0
0
0
Net Income
-31
-22
-28
-22
-22
-18
-18
-11
-13
-19
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
92.95%
100.00%

Enanta Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Total Revenue
102
206
205
122
97
86
79
67
65
Gross Profit
102
206
205
122
97
86
79
67
60
Operating Income
24
88
36
-41
-109
-123
-137
-121
-85
EBITDA
26
90
39
-37
-104
-119
-123
-104
-70
Interest Expense
0
4
-
-
-
-
5
10
7
Depreciation
2
2
3
3
3
2
2
2
5
Income Before Tax
26
93
45
-35
-107
-122
-130
-117
-83
Income Tax Expense
9
21
0
1
-28
0
2
-1
-1
Net Income
17
71
46
-36
-78
-121
-133
-116
-81
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
92.98%

Enanta Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-31
-22
-28
-22
-22
-18
-18
-11
-13
-19
Operating Cash Flow
-28
-14
-10
-16
-13
17
-6
-11
-7
-9
Investing Cash Flow
58
-6
19
68
-4
-26
2
-47
11
14
Financing Cash Flow
-6
-6
-7
-4
-6
-6
-8
64
-7
-5
Change in Cash
23
-27
1
47
-24
-15
-12
5
-2
-1

Enanta Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Sep 2017
Sep 2018
Sep 2019
Sep 2020
Sep 2021
Sep 2022
Sep 2023
Sep 2024
Sep 2025
Net Income
17
71
46
-36
-78
-121
-133
-116
-81
Operating Cash Flow
52
29
71
7
-69
-84
-103
-78
-19
Investing Cash Flow
-4
-35
-86
19
36
54
-53
58
40
Financing Cash Flow
1
4
2
8
3
20
198
-27
-26
Change in Cash
49
-1
-12
35
-29
-9
41
-48
-5

Global Institutional Holdings in Enanta Pharmaceuticals

Check out the Institutions with significant holdings in Enanta Pharmaceuticals.

Funds
Holdings
Andrew J.M. Spokes
8.30%
iShares
4.90%
Vanguard
4.90%
VANGUARD INDEX FUNDS
3.95%
BlackRock Funds
2.04%

Enanta Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 23 June

    Tue, 02:40 PM

    -

    AbbVie receives EU approval for MAVIRET, a significant treatment for acute Hepatitis C, benefiting Enanta's partnership.

    Wed, 04:20 AM

    -

    U.S. Court of Appeals invalidates Enanta's patent claims against Pfizer regarding Paxlovid, impacting its IP strategy.

Insights on Enanta Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ENTA stock has moved up by 9.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 541.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 82.2% return, outperforming this stock by 53.4%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 18.61M → 14.35M (in $), with an average decrease of 12.1% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -11.93M → -19.50M (in $), with an average decrease of 29.3% per quarter

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
OrganisationEnanta Pharmaceuticals
Headquarters4 Kingsbury Avenue, Watertown, MA, 02472, US
IndustryBiotechnology
CEOJay R. Luly

Key Management of Enanta Pharmaceuticals

Name

Title

Mr. Matthew P. Kowalsky J.D.

Chief Legal Officer & Corporate Secretary

Mr. Nathaniel S. Gardiner J.D.

Consultant

Ms. Tara Lynn Kieffer Ph.D.

Chief Product Strategy Officer

Mr. Brendan Luu

Chief Business Officer

Ms. Kathleen S. Capps CPA

Executive Director of Accounting, Controller & Interim Principal Accounting Officer

Ms. Jennifer Viera

Executive Director of Investor Relations & Corporate Communications

Dr. Jay R. Luly Ph.D.

President, CEO & Director

Dr. Yat Sun Or Ph.D.

Chief Scientific Officer

Dr. Scott T. Rottinghaus M.D.

Chief Medical Officer

Mr. Harry R. Trout III

VP of Finance & Interim Principal Financial Officer

FAQs

What is Enanta Pharmaceuticals share price today?

Enanta Pharmaceuticals share price today is $12.96 as on at the close of the market. Enanta Pharmaceuticals share today touched a day high of $13.21 and a low of $12.58.

What is the 52 week high and 52 week low for Enanta Pharmaceuticals share?

Enanta Pharmaceuticals share touched a 52 week high of $17.15 on and a 52 week low of $10.12 on . Enanta Pharmaceuticals stock price today i.e. is closed at $12.96,which is 24.43% down from its 52 week high and 28.01% up from its 52 week low.

What is Enanta Pharmaceuticals's market capitalisation today?

Enanta Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Enanta Pharmaceuticals Stock (ENTA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Enanta Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Enanta Pharmaceuticals Stock (ENTA) from India?

Indian investors can start investing in Enanta Pharmaceuticals (ENTA) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Enanta Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Enanta Pharmaceuticals share’s latest price of $12.96 as on October 3, 2026 at 8:45 am IST, you will get 0.7716 shares of Enanta Pharmaceuticals. Learn more about fractional shares .

What are the returns that Enanta Pharmaceuticals has given to Indian investors in the last 5 years?

Enanta Pharmaceuticals stock has given -78.74% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?